How big is Supernus Pharmaceuticals, Inc.?

As of Jun 18, Supernus Pharmaceuticals, Inc. has a market capitalization of $1.81 billion, with net sales of $668 million and a net profit of $62 million over the latest four quarters.

Market Cap: As of Jun 18, Supernus Pharmaceuticals, Inc. has a market capitalization of 1,809.86 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Supernus Pharmaceuticals, Inc. reported net sales of 667.99 million and a net profit of 61.92 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1,035.73 million and total assets of 1,500.81 million.

What does Supernus Pharmaceuticals, Inc. do?

Supernus Pharmaceuticals, Inc. is a micro-cap pharmaceutical company focused on developing treatments for central nervous system diseases, with recent net sales of $150 million and a net profit of -$12 million. The company has a market cap of approximately $1.81 billion.

Overview: <BR>Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 150 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -12 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,809.86 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 29.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.44 <BR>Return on Equity: 6.24% <BR>Price to Book: 1.76<BR><BR>Contact Details: <BR>Address: 9715 Key West Avenue, ROCKVILLE MD: 20850 <BR>Tel: 1 301 8382500 <BR>Website: https://www.supernus.com

Should I buy, sell or hold Supernus Pharmaceuticals, Inc.?

Who are in the management team of Supernus Pharmaceuticals, Inc.?

As of March 2022, the management team of Supernus Pharmaceuticals, Inc. includes Independent Chairman Mr. Charles Newhall, President and CEO Mr. Jack Khattar, and Independent Directors Dr. Carrolee Barlow, Dr. Georges Gemayel, Mr. Frederick Hudson, and Dr. John Siebert. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Supernus Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Mr. Charles Newhall, who serves as the Independent Chairman of the Board.<BR>- Mr. Jack Khattar, who holds multiple roles as President, Chief Executive Officer, Secretary, and Director.<BR>- Dr. Carrolee Barlow, who is an Independent Director.<BR>- Dr. Georges Gemayel, also an Independent Director.<BR>- Mr. Frederick Hudson, serving as an Independent Director.<BR>- Dr. John Siebert, who is another Independent Director.<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Is Supernus Pharmaceuticals, Inc. technically bullish or bearish?

As of August 18, 2025, Supernus Pharmaceuticals, Inc. shows a strong bullish trend supported by positive technical indicators, outperforming the S&P 500 with a 7.30% return over the past month and 44.88% over the past year.

As of 18 August 2025, the technical trend for Supernus Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view: the MACD is bullish on both weekly and monthly timeframes, Bollinger Bands are bullish, and moving averages are bullish on a daily basis. The KST is also bullish on both weekly and monthly charts. However, the Dow Theory indicates a mildly bullish stance on both timeframes. <BR><BR>In terms of performance, Supernus has outperformed the S&P 500 over the past month with a return of 7.30% compared to the S&P 500's 2.33%, and over the past year with a return of 44.88% against the S&P 500's 17.14%. Overall, the technical indicators suggest a strong bullish sentiment for the stock.

Is Supernus Pharmaceuticals, Inc. overvalued or undervalued?

As of October 17, 2025, Supernus Pharmaceuticals, Inc. is considered overvalued with a P/E ratio of 29 and an EV to EBITDA of 9.02, despite a strong year-to-date return of 38.74%, especially when compared to lower valuation metrics of competitors like PTC Therapeutics and Harmony Biosciences.

As of 17 October 2025, the valuation grade for Supernus Pharmaceuticals, Inc. has moved from very attractive to expensive, indicating a shift towards overvaluation. The company appears overvalued based on its current metrics, with a P/E ratio of 29, an EV to EBITDA of 9.02, and a Price to Book Value of 1.80. In comparison, PTC Therapeutics, Inc. has a P/E ratio of 5.85 and EV to EBITDA of 3.17, while Harmony Biosciences Holdings, Inc. shows a more favorable P/E of 11.40 and EV to EBITDA of 6.94, highlighting the relative overvaluation of Supernus.<BR><BR>Despite the company's strong recent performance, with a year-to-date return of 38.74% compared to the S&P 500's 13.30%, the elevated valuation ratios suggest that the stock may not be a sustainable investment at its current price level.